首页 | 本学科首页   官方微博 | 高级检索  
检索        

氨曲南治疗肿瘤患者下呼吸道感染的成本-效果分析
引用本文:裴保香,徐燕萍.氨曲南治疗肿瘤患者下呼吸道感染的成本-效果分析[J].中国药物应用与监测,2008,5(4):27-28.
作者姓名:裴保香  徐燕萍
作者单位:解放军总医院药品保障中心,北京,100853
摘    要:目的:评价氨曲南治疗肿瘤患者下呼吸道感染的成本-效果,促进合理用药,降低医疗费用。方法:利用已有文献资料,运用药物经济学成本-效果分析方法,对氨曲南与头孢他啶治疗肿瘤患者下呼吸道感染进行药物经济学评价。结果与结论:两组方案治疗肿瘤患者下呼吸道感染的临床有效率、治愈率无显著性差异,但氨曲南组的细菌清除率优于头孢他啶组,头孢他啶的经济学成本优于氨曲南。

关 键 词:氨曲南  头孢他啶  肿瘤患者  下呼吸道感染  成本-效果分析

Cost-effectiveness analysis of aztreonam in the treatment of cancer patients with lower respiratory tract infection
Authors:PEI Bao-xiang  XU Yan-ping
Institution:(Department of Pharmaceutical Care, PLA General Hospital, Beijing, 100853)
Abstract:Objective: To evaluate the cost-effectiveness of aztreonam in the treatment of cancer patients with lower respiratory tract infection,promote rational use of the drugs and decrease the treatment cost. Methods: The cost-effectiveness was analyzed with medical cost-effectiveness analyzing method aztreonam and ceftazidime were compared in the treatment of cancer patients with lower respiratory tract infection based on the published reference data. Results and Conclusion: There is no obvious difference between these two drugs in clinical effective rate and cure rate of cancer patients with lower respiratory tract infection,but the bacteria clear-ance ratio of aztreonam was superior to that of ceftazidime. Cost-effectiveness ratio of ceftazidime is superior to that of aztreonam.
Keywords:Aztreonam  Ceftazidime  Cancer patients  Lower respiratory tract infection  Cost-effectiveness analysis
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号